Table 2.
Phase III trials comparing first-line treatment of EGFR TKIs to chemotherapy on patients with EGFR-positive mutation status
| Study (reference) | Treatments | PFS (months) | OS (months) |
|---|---|---|---|
| IPASS [32, 34]a | Gefitinib vs carbo/paclitaxel | 9.5 vs 6.3 | 21.6 vs 21.9 |
| First-SIGNAL [35] | Gefitinib vs cis/gem | 8 vs 6.3 | 27.2 vs 25.6 |
| WJTOG3405 [36] | Gefitinib vs cis/doce | 9.2 vs 6.3 | 36 vs 39 |
| NEJSG [37] | Gefitinib vs carbo/paclitaxel | 10.8 vs 5.4 | 30.5 vs 23.6 |
| EURTAC [38] | Erlotinib vs chemotherapy | 9.7 vs 5.2 | 19.3 vs 19.5 |
| OPTIMAL [39] | Erlotinib vs carbo/gem | 13.1 vs 4.6 | 22.7 vs 28.9 |
| LUX-Lung 3 [33]** | Afatinib vs cis/pemetrexed | 11.1 vs 6.9 | 16.6 vs 14.8b |
PFS progression-free survival, OS overall survival
a
IPASS study included East Asians with advanced pulmonary adenocarcinoma who were light or never smokers; the data above represents the EGFR-positive subgroup of the randomized study
b
Preliminary OS data (25th percentile), not statistically significant